Higher Brain Temperature in Youth Bipolar Disorder Using a Novel Magnetic Resonance Imaging Approach

Highlights from Posters Presented at the Society of Biological Psychiatry Meeting, April 27-29, 2023 in San Diego

Ben Goldstein of the University of Toronto reported that “Brain temperature was significantly higher in BD (bipolar youth) compared to CG (control group) in the precuneus. Higher ratio of brain temperature-to-CBF [cerebral blood flow] was significantly associated with greater depression symptom severity in both the ACC [anterior cingulate cortex] and precuneus within BD.”

These finding are of particular interest in light of the Unspecified Bipolar Disorder subtype called Temperature and Sleep Dysregulation Disorder (TSDD), where patients are over heated and respond to clonidine and other cooling techniques along with lithium and repeated intranasal ketamine insufflations.

Low Frequency rTMS for Treatment-Resistant Auditory Hallucinations in Schizophrenia

Highlights from Posters Presented at the Society of Biological Psychiatry Meeting, April 27-29, 2023 in San Diego:

J. Brunelin gave patients “30 sessions of 1 Hz rTMS (repetitive Transcranial magnetic stimulation) over 3 weeks (360 pulses per sessions delivered with 60 sec ‘on’ and 30 sec ‘off’ at 110% of the resting motor threshold, 2 sessions per day). Stimulations were applied over the left temporoparietal junction.” Severity of auditory verbal hallucinations decreased (p=0.003) including in the 9 patients included with clozapine-resistant symptoms.

An Open Label Study of Synthetic Psilocybin in Bipolar Type II Depression

Highlights from Posters Presented at the Society of Biological Psychiatry Meeting, April 27-29, 2023 in San Diego

Scott Aaronson reported on patients receiving a single dose of synthetic psilocybin. All subjects had three preparatory sessions prior to dosing and three integration sessions post dosing and were followed for 12 weeks.

“At the three week primary outcome measure, 11 of 14 participants (78.6%) met remission criteria.” They concluded: “Most subjects reported significant improvement in chronic depressive symptoms without hypomania or suicidality and durability lasting for three months follow-up.”

The Addition of Fish Oil to Cognitive Behavioral Case Management is Not Effective for Youth Depression

In a relatively large placebo-controlled study adding a combination of 840 mg of eicosapentaenoic acid (EPA) and 560 mg of docosahexaenoic acid (DHA) versus placebo did not help treat depressed youth undergoing cognitive behavioral case management (CBCM) (Amminger et al, Biol. Psychiatry, June 22, 2023).

These findings add to the ongoing inconsistency of the effectiveness of Omega 3 Fatty Acids in treating depression. It had appeared more effective in younger than older depressed patients, but now even this trend appears unreliable.

A meta analysis does support use Omega 3 Fatty Acids for ADHD, however.

Vortioxetine Improves Cognition, Major Depression in Early Dementia

    Vortioxetine (5mg then 10mg) significantly improves depressive symptoms, cognitive performance, functioning, and quality of life at 12 weeks in patients with both major depressive disorder (MDD) and early-stage dementia.  In addition to blocking 5HT (serotonin) reuptake vortioxetine antagonizes 5 serotonin receptors with 5HT3 and 5HT7 likely accounting for the positive effects on processing speed and cognitive functioning.

Cannabis Use Disorder Increases Risk of Subsequent Unipolar Depression and Bipolar Disorder

Jefsen et al report in JAMA Psychiatry. that in “[6,651,765] individuals in Demark, cannabis use disorder was associated with an increased risk of (subsequent) both psychotic and nonpsychotic unipolar depression and bipolar disorder….Associations between CUD and subsequent affective disorders were estimated as hazard ratios (HRs) using Cox proportional hazards regression with time-varying information on CUD, adjusting for sex; alcohol use disorder; substance use disorder; having been born in Denmark; calendar year; parental educational level (highest attained); parental cannabis, alcohol, or substance use disorders; and parental affective disorders….Cannabis use was associated with an increased risk of bipolar disorder in men (HR, 2.96; ) and women (HR, 2.54; )”, and was highest for psychotic bipolar disorder (HR, 4.05; 95% CI, 3.52-4.65).

Editors Note: Marijuana is not a benign substance. “In all, 60,?696 individuals received a diagnosis of (cannabis use disorder) during follow-up, and 260,?746 (3.9%) developed an affective disorder.”

The Cognitive Effects of Electroconvulsive Therapy in Community Settings

Harold Sackeims’ review in Neuropsychopharmacology, 32, 244-254 (2007) remains one of the best updates indicating that the cognitive effects of Electroconvulsive Therapy (ECT) are not always benign. They followed 347 patients from seven facilities in New York city and tested them after their last session of ECT and then again 6 months later. They reported that “Electrical waveform and electrode placement had marked cognitive effects. Sine wave stimulation resulted in pronounced slowing of reaction time, both immediately and 6 months following ECT. Bilateral (BL) ECT resulted in more severe and persisting retrograde amnesia than right unilateral ECT. Advancing age, lower premorbid intellectual function, and female gender were associated with greater cognitive deficits. Thus, adverse cognitive effects were detected 6 months following the acute treatment course. Cognitive outcomes varied across treatment facilities and differences in ECT technique largely accounted for these differences. Sine wave stimulation and BL electrode placement resulted in more severe and persistent deficits.”

Editors note: This is why it is important to recommend right unilateral ultra brief pulse (RUUBP) ECT both for acute and continuation treatment if necessary. Continuing RUUBP ECT rather than converting to bilateral ECT would appear to be preferable.

Obesity is associated with reduce cortical thickness in bipolar disorders

Sean R. McWhinney et al reported in Psychological Medicine (2023) that obesity was associated with reduced cortical thickness (but not surface area) in most areas of the brain in 2832 participants.

Editors Note: Patients and clinicians should try to prevent and reduce weight gain using the best tolerated medications from the outset and helping with weight loss by various measures. These can include the anticonvulsants topiramated and zonisamine, the combination of bupropion and naltrexone, and the use of new anti-diabetic drugs such as Jardiance and Farxiga that have weight loss (greater than with metformin) as a side effect. Prescribing a good diet and regular exercise is also indicated. Reducing obesity will likely make you live longer and maybe could even make you smarter.

Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomized clinical trial

von Rotz et al reported in eClinical Medicine (the Lancet) that a single dose of psilocybin produced a huge AD (anti-depressant) effect compared to placebo. A dose of 0.215mg Kg (about 15mg for a 70kg person) had a rapid onset AD effect that persisted for at least 14 days. Music was played and in a living room like environment. Psychological support was provided on 3 visits pretreatment and on days 8 and 14 for a total of 14 hours

Familial Aggregation of Major Depression Predicts Risk of Major Depression

Gronemann et al reported in JAMA Psychiatry: “In this cohort study of 2,903,430 individuals, maternal, paternal, full sibling, or half-sibling with MD were associated with 2-fold higher risks of MD in men and women….(E)xposure to family MD during childhood and adolescence was associated with increased risk. The risk increased with number of affected family members; (however) individuals exposed when 30 years or older had markedly lower risk.

Editors Note: Even depression in grandparents adds further to the risk of depression.  When there is high familial loading for depression and other psychiatric illnesses, one should be alert to the possible onset of depression in young individuals and treat them early and well accordingly.

« Previous PageNext Page »